Horse Sport Enews SIGN UP More from News:MARS Bromont CCI Announces Requirements For US-Based RidersThe first set of requirements to allow American athletes and support teams to enter Canada for the June 2-6 competition have been released.Canadian Eventer Jessica Phoenix Reaches the 100 CCI4*-S MarkPhoenix achieved the milestone while riding Pavarotti at the inaugural 2021 CCI4*-S at the Land Rover Kentucky Three-Day Event.Tribunal Satisfied That Kocher Made Prolonged Use of Electric SpursAs well as horse abuse, the US rider is found to have brought the sport into disrepute and committed criminal acts under Swiss law.Washington International Horse Show Returns to TryonTIEC will again provide the venue for the WIHS Oct. 26-31 with a full schedule of hunter, jumper and equitation classes. Subscribe to the Horse Sport newsletter and get an exclusive bonus digital edition! Email* We’ll send you our regular newsletter and include you in our monthly giveaways. PLUS, you’ll receive our exclusive Rider Fitness digital edition with 15 exercises for more effective riding. Top seller D’Amour went for 260,000 euros. (Feldhaus photo)Exciting bidding duels until the very last second comprised the 94th Oldenburg Online Elite Auction in Vechta, Germany. The four-year-old dressage prospect D‘Amour (D’Egalité – Ampère – De Niro), bred by Klaus Kotschofsky, Visbek, and exhibited by Gut Feichten Sportpferde Management GbR of Bad Tölz, was the top seller, fetching 260,000 euros. Her dam, Beauty Girl, is the sister of Intermediaire II winner Ratzeputz under Ursula Wagner. The Hamburg buyer tried out the mare in Vechta and fell in love with the beautiful prima ballerina.The second most expensive dressage horse at 125,000 euros was the eight-year-old Toscana (Tomahawk – Welt Hit II – Ordensglanz/T.), bred by Anne Weser of Stavern, and exhibited by Pferdezucht FE René Eberz of Montabaur. The beautiful mare is a daughter of Oldenburg star sire Tomahawk and sister of the successful advanced-level Fifty Cent (ridden by Helena Bicker) and Lorenzio (Juan Manuel Vidal Testal, ESP). In the future Toscana will reside in Great Britain.For 108,000 euros, the stallion Dovizioso by Dancier – Sunny-Boy – Rubinstein I, bred by Thaden & Tienken-Thaden of Butjadingen and exhibited by Gestüt Vorwerk of Cappeln, sold to a dressage stable in Belgium. Doviziosos brother Dan Roy is successful in Prix St. Georges under Heiner Schiergen. Granddam Romantik TS is sister of the sire Dream of Glory.A mare also topped the price list in the jumper division. The top seller was the four-year-old OS Champion mare Only You (Ogano – Balou du Rouet – Lord Liberty), bred by Katja Schwierking of Barver and exhibited by Arndt Schwierking. Her dam, Sunshine’s Botox, produced the 1.40 m and higher successful El Balou OLD (ridden by Lillie Keenan, USA), Cirby (Romain Duguet, SUI), Channing Tatum (Katharina Offel) and Cornet’s Baloufee (Piergiorgio Bucci, ITA). The lovely mare moved to a renowned jumping stable in Mexico for 88,000 euros.Second most expensive jumper was the grey mare Galla Hillock (Cornettino Ask – Contender – Capitol I), bred and exhibited by Stutteri Hillock of Denmark. The OS high flyer changed hands for 83,500 euros to a buyer in Hungary. Galla Hillock’s sister Cavallina was an auction price highlight two years ago in Vechta. Dam Unica VII is the sister of the successful 1.40 m athletes Cosmo de Bonnevieux (Karin Haber, SUI), Crispien (Georgia Tame, GBR), Continuum (Teddy Thellier, FR), and Corinessa (Eva-Maria Müller).Biasini (Bordeaux – Fürst Romancier – Kondor xx) was sold to an undisclosed Canadian buyer for 30,000 euros.Fifteen of the 31 auction candidates were knocked down by customers from all over the world. Customers from Belgium (3), Great Britain (2), Switzerland (2), Ireland (1), Italy (1), Canada (1), Mexico (1), Portugal (1), Spain (1), Hungary (1), and the United States (1) will be taking home talented Oldenburgs to ride. The four-year old chestnut mare Biasini (Bordeaux – Fürst Romancier – Kondor xx) was sold to an undisclosed Canadian buyer for 30,000 euros.Watch a video of Biasini here: The total sales of the first part of the Online Elite Auction reached 1,508,500 euros; the average price of the horses was more than 48,500 euros.On Sunday, April 11, the licensing candidates of the 10th Oldenburg Saddle Licensing that are up for sale will be published with photos, videos and information in the auction section of the Oldenburg home page www.oldenburger-pferde.com. The saddle licensing will take place on Monday, April 19. The Online Auction starts on April 19 and ends on Wednesday, April 21.~ with files from Tobias Hemken Tags: Dressage, Biasini, jumping, auction, Vechta, Oldenburg,
___________________________________________________________________________________________Comments are currently unavailable. We’re working on the development of a NASCAR fan forum – please stay tuned.
Joseph Mariathasan explores the impact of – and possible solution to – the growing dengue epidemicSummer is approaching, and as thoughts for many turn to what preparations may be required for holidays in the sun, travellers to tropical regions may be looking at stocking up on malaria tablets. These can, in some cases, have rather nasty side effects, but those travelling to Sri Lanka, for example, may not need to bother, as it may become the first-ever tropical country to eliminate malaria officially (if no one is reported with it by October this year).However, whilst malaria may be absent in Sri Lanka, and anti-malaria tablets can, if required, be taken for travel elsewhere, there is another mosquito-borne disease – dengue – that travellers need to be aware of. It causes a severe flu-like illness and can sometimes lead to a potentially lethal complication called dengue haemorrhagic fever. The WHO finds that Central and South America, South-East Asia and the Western Pacific are the most seriously affected regions in the world. What that means is that some 2.5bn people – two-fifths of the world’s population – are now at risk of acquiring dengue. That includes countries such as Brazil, currently preparing for the 2016 Olympics, and popular tourist destinations such as Thailand, with upwards of 25m visitors a year.Estimates of people getting dengue each year are very unreliable, as the symptoms are easily confused with flu and in many cases may be very mild and, as such, unreported. Why dengue is becoming a serious burden for countries is that, according to WHO, up to 50m infections occur annually, with 500,000 cases of dengue haemorrhagic fever and 22,000 deaths, mainly among children. Prior to 1970, only nine countries had experienced cases of dengue haemorrhagic fever. Since then, the number has increased more than fourfold and continues to rise. Some academics have estimated actual dengue cases are probably closer to 400m a year, and there are approaching 100m that have pronounced symptoms. Others have estimated that dengue is now becoming more dangerous than malaria in terms of economic impact and morbidity. Whilst dengue is becoming a major global health issue, there may also be a solution, or rather, a number of solutions. Vaccines are currently being developed by a number of companies, and clinical trials are well under way. The illness itself is caused by one of four variations (serotypes) of a virus. Catching one serotype gives a person immunity for life to that specific serotype. However, it also appears to raise the chances of complications if there is a subsequent infection by a different serotype, and that can result in dengue haemorrhagic fever, which can be fatal. Therefore, any vaccine has to be effective against all four serotypes to give complete immunity.Given dengue’s economic impact, it is unsurprising there is a race to develop a dengue vaccine. Whoever succeeds will potentially save countless lives and alleviate much misery but also profit from an immense market opportunity. What is encouraging for everyone, including investors, is that there does appear to be a real chance of success within the next year or two. Currently, Sanofi Pasteur, the vaccines division of French pharmaceutical company Sanofi, has received a fair amount of attention because it has announced results for clinical trials of a vaccine that shows an overall efficacy against any symptomatic dengue disease of 60.8% in children and adolescents.Whilst this may not sound like a solution, it reported a 95.5% protection against severe dengue and an 80.3% reduction in the risk of hospitalisation during the study. Sanofi Pasteur itself is so confident of its vaccine that it has built a new vaccine-manufacturing facility in France with the objective of reducing the time necessary to provide access to the vaccine once it is licensed. It became operational in 2014 with a production capacity of 100m doses of the vaccine per year. Sanofi, though, is not the only firm working on vaccines. It is highly likely that, within the next year or two, there will be announcements of breakthroughs by firms such as Japan’s Takeda Pharmaceutical, which is undertaking phase-III clinical trials in Sri Lanka and four other Asian countries. The race for a successful dengue virus is well and truly under way.Joseph Mariathasan is a contributing editor at IPE